Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Accéder directement au contenu
Article Dans Une Revue Lancet Oncology Année : 2017

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

1 Istituto Nazionale Tumori Fondazione Pascale [Naples, Italy]
2 Medical Oncology, National Cancer Institute [Milan, Italy]
3 IGR - Institut Gustave Roussy
4 Department of Diagnostics and Cancer Immunology [Poznan, Poland]
5 Melanoma Oncology Unit [Padova, Italy]
6 Hospital Clinic - Institut d'Investigacions Biomèdiques August Pi I Sunyer [Barcelona, Spain]
7 IDO (U976 / UMR_S 976) - Immunologie, dermatologie, oncologie ; Oncodermatologie, immunologie et cellules souches cutanées
8 Odense University Hospital [Odense, Denmark]
9 Cedars-Sinai Medical Center
10 Maria Sklodowska-Curie Memorial Cancer Center [Warsaw, Poland]
11 RPAH - SYDNEY - Royal Prince Alfred Hospital
12 Melanoma Institute Australia [Sydney, NSW, Australia]
13 Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen
14 University Medical Center [Mainz, Germany]
15 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers
16 Département de Dermatologie [CH Lyon-Sud, Pierre-Bénite]
17 TIMONE - Hôpital de la Timone [CHU - APHM]
18 National Institute of Oncology [Budapest, Hungary]
19 Oslo University Hospital [Oslo]
20 Medizinische Hochschule Hannover [Hannover, Germany]
21 Wojewodzkie Centrum Oncologii [Gdańsk, Poland]
22 Hôpital universitaire Robert Debré [Reims]
23 Medizinische Universität Wien = Medical University of Vienna
24 Istituti Fisioterapici Ospitalieri [Rome, Italy]
25 Cross Cancer Institute [Edmonton, AB, Canada]
26 AöR - University Hospital Essen
27 Hôpital Claude Huriez [Lille]
28 Herlev and Gentofte Hospital
29 Bristol-Myers Squibb [Princeton]
30 Istituto Toscano Tumori [Siena, Italy]
Caroline Robert
Jean-Jacques Grob
Laurent Mortier
Michele Maio
  • Fonction : Auteur
  • PersonId : 899117

Résumé

BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg. METHODS: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses. Patients were stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperative Oncology Group performance status. The patients, investigators, and site staff were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment. This study is completed and was registered with ClinicalTrials.gov, number NCT01515189. FINDINGS: Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6-42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9-29·4) for the ipilimumab 3 mg/kg group. Median overall survival was 15·7 months (95% CI 11·6-17·8) for ipilimumab 10 mg/kg compared with 11·5 months (9·9-13·3) for ipilimumab 3 mg/kg (hazard ratio 0·84, 95% CI 0·70-0·99; p=0·04). The most common grade 3-4 treatment-related adverse events were diarrhoea (37 [10%] of 364 patients in the 10 mg/kg group vs 21 [6%] of 362 patients in the 3 mg/kg group), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypophysitis (ten [3%] vs seven [2%]). Treatment-related serious adverse events were reported in 133 (37%) patients in the 10 mg/kg group and 66 (18%) patients in the 3 mg/kg group; four (1%) versus two (<1%) patients died from treatment-related adverse events. INTERPRETATION: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival than did ipilimumab 3 mg/kg, but with increased treatment-related adverse events. Although the treatment landscape for advanced melanoma has changed since this study was initiated, the clinical use of ipilimumab in refractory patients with unmet medical needs could warrant further assessment.

Domaines

Cancer
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-01807340 , version 1 (04-06-2018)

Identifiants

Citer

Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, Andrzej Mackiewicz, Vanna Chiarion-Sileni, et al.. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩. ⟨inserm-01807340⟩
208 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More